L-Asparaginase (ASNase) has been applied as a first-line treatment for acute lymphoblastic leukemia (ALL) since the 1970s until today, as its antitumor activity increases the5 year disease-free survival rate to 90%. This evidence concerns the gene ASPG and acute lymphoblastic leukemia.